NH TherAguix
France - MeylanBiotechnology
Focus: NH TherAguix is a French biotech specializing in tumor-targeting nanoparticle technology (AGuIX®) for oncology indications, particularly brain metastases. The company operates as a focused pre-revenue biotech with a single lead platform in early-to-mid clinical development.
Profile data last refreshed 10h ago · AI intelligence enriched 1w ago
Open Jobs
1
Should You Work at NH TherAguix?
AI assessmentNH TherAguix suits early-career researchers and clinical scientists seeking platform-technology exposure in oncology, but financial opacity and minimal hiring activity signal caution for career-stage professionals prioritizing stability.
Why Work Here
- Opportunity to work on differentiated nanoparticle technology with three active clinical programs across brain metastases and NSCLC indications.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AGuIX
Brain MetastasesClinical Trials (1)
NCT02820454Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles
Phase 1Help build intelligence for NH TherAguix
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.